EUVIMEDEUVIMED entdecken
Crossref

Discovery of 3-phenyl-1H-5-pyrazolylamides as PLpro inhibitors through virtual screening and structure optimization

Chengwei Wu, Mengdie Ou, Bo Qin, Shuo Wang, Peng Li, Sheng Cui, Haihong Huang, Gang Li

Bioorganic & Medicinal Chemistry Letters · 2025

DOI: 10.1016/j.bmcl.2025.130293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2025. Verfasst von Chengwei Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chine…. Hauptthemen laut MEDLINE: Pyrazoles, Drug Discovery, SARS-CoV-2, Coronavirus 3C Proteases. Die Arbeit nennt 29 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The papain-like protease (PLpro) of SARS-CoV-2 has been identified as a pivotal enzyme in viral replication, indicating it a promising target for drug discovery. Utilizing a virtual screening strategy, compound 1 with the N-(3-(5-amino-1H-pyrazol-3-yl)phenyl) benzenesulfonamide scaffold was discovered as a hit targeting PLpro. Structural modification from virtually screened hit 1 led to the development of a series of substituted 3-phenyl-1H-5-pyrazolylamide derivatives. Notably, compounds 14h and 14e exhibited improved PLpro inhibitory activity (IC50 = 14.2 μM and 12.0 μM, respectively) and low cytotoxicity. Further biological evaluation revealed that compound 14e with a thiophene aldehyde group displayed potent binding activity (KD = 1.86 μM). This 3-phenyl-1H-5-pyrazolylamide scaffold offers significant potential for further development as a novel class of PLpro inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesDrug DiscoverySARS-CoV-2Coronavirus 3C ProteasesAntiviral AgentsProtease InhibitorsStructure-Activity RelationshipHumansMolecular Docking SimulationMolecular StructureDrug Evaluation, PreclinicalDose-Response Relationship, Drug

Stichwörter der Autor:innen

3-Phenyl-1H-5-pyrazolylamidePLproStructure optimizationVirtual screening

Substanzen

PyrazolesCoronavirus 3C ProteasesAntiviral Agents3C-like proteinase, SARS-CoV-2Protease Inhibitors

Autor:innen und Institutionen

  • Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, PR China.
  • Key Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 102629, PR China.
  • Key Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 102629, PR China…
  • Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, PR China; State Key La…

Förderung

  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Wu, C., Ou, M., Qin, B., Wang, S., Li, P., Cui, S., Huang, H., & Li, G. (2025). Discovery of 3-phenyl-1H-5-pyrazolylamides as PLpro inhibitors through virtual screening and structure optimization. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2025.130293

Vancouver

Wu C, Ou M, Qin B, Wang S, Li P, Cui S, et al. Discovery of 3-phenyl-1H-5-pyrazolylamides as PLpro inhibitors through virtual screening and structure optimization. Bioorganic & Medicinal Chemistry Letters. 2025. doi:10.1016/j.bmcl.2025.130293

BibTeX
@article{Wu2025,
  author = {Wu, Chengwei and Ou, Mengdie and Qin, Bo and Wang, Shuo and Li, Peng and Cui, Sheng and Huang, Haihong and Li, Gang},
  title = {Discovery of 3-phenyl-1H-5-pyrazolylamides as PLpro inhibitors through virtual screening and structure optimization},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2025},
  doi = {10.1016/j.bmcl.2025.130293}
}
Kostenlos starten →